ClinicalTrials.gg
Enrolling by invitationNCT07458308Updated Apr 13, 2026

Comparison of Blended Care Outpatient Neurorehabilitation With Traditional Outpatient Neurorehabilitation

An interventional study of Blended care outpatient neurorehabilitation in Stroke, Intracerebral Haemorrhage and Brain Trauma, sponsored by Luzerner Kantonsspital. Enrolling by invitation at 1 site in Switzerland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Luzerner Kantonsspital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.

Planned enrollment
108th of 147
30 · median 79
Started
2026
with 11 others
No phase
95 of 216
24 open now
Primary completion
2029-03
later than 46 of 59 live
Registered
205th of 216
by date
Lead sponsor
6 of 216
Luzerner Kantonsspital

Among the 216 studies in Stroke with a site in Switzerland, this one is the 108th largest by planned enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2026, is one of 95 with no phase, reaches primary completion later than 46 of the 59 other live ones, and was the 205th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Stroke with a site in Switzerland, or all of them as a file.
02

Study summary

What is this study about? Outpatient neurorehabilitation (therapy after leaving the hospital) is an important follow-up treatment for people who have had a stroke, brain bleeding, or serious head injury. It helps improve problems with movement, speech, memory, or daily activities.

At the same time, there are not enough healthcare professionals, and healthcare costs are rising. Because of this, we need new and more efficient ways to provide therapy.

One possible solution is telerehabilitation. This means patients do part of their therapy at home using video calls and apps. Early studies show that this can work well. However, in Switzerland it is still rarely used. One reason is that digital therapies are often not paid for, and there is still limited scientific proof of how effective they are.

In this study, the investigators want to find out how well a combination of traditional in-person therapy and digital therapy at home works. The goal is to make treatment more modern, effective, and affordable - benefiting patients, therapists, and the healthcare system.

How is the study organized?

Participants in the study are randomly divided into two groups.

Group 1:

First, participants have three weeks of combined therapy:

  1. therapy day per week at the hospital.
  2. therapy days per week at home via Microsoft Teams video calls. On home days, participants also complete exercises using apps provided by their therapists.

After that, participants have three weeks of therapy fully at the hospital (3 days per week).

Group 2:

First, participants have three weeks of therapy at the hospital (3 days per week).

After that, participants have three weeks of combined therapy (hospital + home video therapy).

Both groups receive the same types of therapy, just in a different order. This is called a crossover design.

Because this is one of the first studies of its kind, the investigators are starting with a small number of participants. This is called a pilot study.

Read the detailed description

During the preparation phase and at different points during the study, participants will complete several tests and questionnaires. These take about 30-60 minutes each.

These tests help the investigators:

Check whether participants are physically stable and safe enough to take part in the therapy sessions.

See how participants' physical and thinking abilities change over time.

During the appointments, participants will do exercises from:

Physiotherapy Occupational therapy And, if needed, speech therapy and language therapy Each therapy session lasts 30-45 minutes.

The exercises are a mix of:

Paper-based exercises Conversations and guided exercises with the therapists Exercises using apps that the participant downloads to his/her phone or tablet during the preparation phase (participants will receive instructions on how to use them)

Benefits and Risks Taking part in this study does not provide a direct personal benefit to the participant.

However, if this system proves to be successful, future patients may benefit from therapy that can be done from home.

There is a risk that the participant may not do the exercises at home with the same intensity as in the therapy clinic. However, since the participant will stay in regular contact with the therapists at home, we expect that this risk will have only a small effect on how well the therapy works.

Another possible risk is that, without a therapist physically present, participants may lose your balance more easily at home, which could lead to a fall and injury.

Before the study begins, we will carry out several tests to make sure participants are able to safely participate in the different therapies. This helps reduce the risk that participants cannot perform the exercises properly at home or get injured from a fall.

Funding and Costs This study is organized and fully funded by Luzerner Kantonsspital. The researchers involved do not receive any direct financial benefit from conducting this study.

Participants will not receive any payment or other compensation for participating.

There will be no additional costs for the participant or the health insurance upon participation.

03

Conditions studied

  • Stroke
  • Intracerebral Haemorrhage
  • Brain Trauma

Keywords

  • outpatient neurorehabilitation
  • Blended care/Telerehabilitation
  • Outcome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ischemic or haemorragic stroke or brain trauma.
  • People for whom at least 6 weeks of outpatient rehabilitation is foreseen to be indicated.
  • Ability for safe independent mobilisation (screening with MiniBesTest, Chedoke)
  • Access to and ability to operate MS Teams and Apps on computer and other digital devices (Smartphone, Tablet) (Screening with , LAST and NHPT)
  • Able to provide in German.
  • Age: 18 - 80 years

Exclusion criteria

Exclusion Criteria:

  • Severe cardiopulmonary disease
  • Other neurological disease than mentioned in the inclusion criteria
  • Inability to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Start with traditional outpatient neurorehabilitation, cross over to blended care after 3 weeks

    traditional outpatient neurorehabilitation consists of a mean of 3 days of interdisciplinary therapies per week on site, blended care consists of 2 days of therapies in home setting and 1 day of therapies on site

    Other: Blended care outpatient neurorehabilitation

  • Experimental
    Start with blended care, cross over to traditional outpatient neurorehabilitation after 3 weeks

    Other: Blended care outpatient neurorehabilitation

Interventions

  • OtherBlended care outpatient neurorehabilitation

    Combination of telerehabilitation in the patients' home setting and outpatient neurorehabilitation on site

06

What researchers measure

Primary outcomes

  1. The change in total sum score between start and end of the 2 phases of the cross over periods on the Lucerne International Classification of Functioning, Disability and Health(ICF) -based Multidisciplinary Observation Scale (LIMOS)

    Minimum Value: 45 Maximum Value: 225 Higher Scores mean better outcome

    Time frame: From start to end of the first crossover phase (Start of study - 3 weeks) and start to end of the second crossover phase (3 weeks - 6 weeks), follow-up at 3 months after end of the whole intervention phase

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Not planned, can be provided upon request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Mar 2029, 35 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 35 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 9, 2026
StartEst.
Apr 7, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Jun 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07458308
Lead sponsor
Luzerner Kantonsspital
Responsible party
Noortje Maaijwee (MD, PhD, Luzerner Kantonsspital) — Principal investigator
First posted
Mar 9, 2026
Start date
Apr 7, 2026 (estimated)
Primary completion
Mar 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Apr 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion